Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
VJHemOnc Podcast
Exploring BTK degraders and their potential in heavily pretreated CLL patients
This chapter explores the creation of BTK degraders, a novel class of drugs designed to bind to and degrade BTK and its scaffolding. Early phase clinical trial data from Nurex and Biogenes revealed promising results in heavily treated patients, with response rates reaching 70% in post-covalent BTK-treated patients.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
